FindTrial
Sign In

Evaluation of the use of Auriculotherapy to improve pain in Tumor Wounds in patients undergoing palliative care

Evaluation of the effects of Auriculotherapy to control pain in lesions or tumor wounds in patients with advanced cancer undergoing palliative care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8h6tk9z
Enrollment
Unknown
Registered
2024-09-19
Start date
2024-10-03
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Pain

Interventions

This is a randomized, blind, two-arm clinical trial involving patients with advanced cancer undergoing palliative care with pain in a wound or tumor lesion. The objective of the study is to evaluate t
E02.190.204

Sponsors

Instituto Nacional do Câncer
Lead Sponsor
Instituto Nacional do Câncer
Collaborator

Eligibility

Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of both sexes in palliative care enrolled at the Cancer Hospital Unit Four (HCIV); patients with pain symptoms of a minimum intensity of four points on the Edmonton Symptom Assessment System (ESAS) scale in the wound/tumor lesion (LFT) located in the skin, breast, head and neck, genitals, rectum or anal canal; patients with FLT staging record (1, 1N, 2, 3 and 4); patients at least 20 years old; patients with (KARNOFSKY PERFORMANCE STATUS SCALE (KPS) greater than 30%, therefore responsive; patients agreeing to sign the Informed Consent Form (ICF)

Exclusion criteria

Exclusion criteria: Patients with injuries to both ear pinnae; patients with adhesive plaster allergy

Design outcomes

Primary

MeasureTime frame
Greater reduction in wound pain and tumor injury is expected in the Intervention Group compared to the Control Group, this development will be measured using the ESAS scale (Edmonton Symptom Assessment System), which consists of a scale that evaluates pain and other symptoms of patients in palliative care, with parameters ranging from 0 to 10, where zero is the absence of the symptom and 10 is the worst possible intensity—

Secondary

MeasureTime frame
A higher proportion of patients with a reduction from 1 to 3 and a reduction greater than 3 points in pain intensity (ESAS-PAIN scale) is expected after 15 minutes and after 24 hours in the IG compared to the CG; a greater reduction in the frequency of opioid analgesic medication consumption is expected after 24 hours in the IG than in the CG—

Countries

Brazil

Contacts

Public ContactBianca Lorrani de Araújo Neves

Instituto Nacional do Câncer José Alencar Gomes da Silva - INCA

biancadearaujoneves@gmail.com+55(21)3207-3700

Outcome results

None listed

Source: REBEC (via WHO ICTRP)